OrigiMed is a medical science and technology transforming company which focuses on developing new technologies and clinical applications for all types of cancer patients. By carrying out more comprehensive and high-throughput methods, leveraging wholesome bioinformatics analysis and clinical annotation, we identify cancer specific molecular markers and genomic features to guide targeted or immuno-therapy, ultimately aiming to fortify the evolution of cancer precision medicine in China.

We are devoted to providing the most comprehensive and accurate molecular
diagnostic information for every cancer patient and for physicians to help
patients get personalized treatment.